Anti-Tumor Drugs Market Research Report by Indications, Route of Administration, Drug, Drug Class, End User, Distribution Channels, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19 – QNT Press Release

[ad_1]

New York, April 20, 2022 (GLOBE NEWSWIRE) — Reportlinker.com announces the release of the report “Anti-Tumor Drugs Market Research Report by Indications, Route of Administration, Drug, Drug Class, End User, Distribution Channels, Region – Global Forecast to 2027 – Cumulative Impact of COVID-19” – https://www.reportlinker.com/p06261929/?utm_source=GNW

The Global Anti-Tumor Drugs Market size was estimated at USD 27.80 billion in 2021 and expected to reach USD 31.13 billion in 2022, and is projected to grow at a CAGR 12.14% to reach USD 55.30 billion by 2027.

Market Statistics:
The report provides market sizing and forecast across five major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2019 and 2020 are considered historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered the forecast period.

Market Segmentation & Coverage:
This research report categorizes the Anti-Tumor Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Indications, the market was studied across Breast Cancer, Leukemia, Lung Cancer, Melanoma, and Prostate Cancer.

Based on Route of Administration, the market was studied across Intra-muscular, Intraperitoneal, Intravenous, Intraventricular / Intrathecal, Intravesicular, Oral, Subcutaneous, and Topical.

Based on Drug, the market was studied across Alkylating Agents, Antimetabolites, Antitumor Antibiotic., Mitotic Inhibitors, and Topoisomerase Inhibitors.

Based on Drug Class, the market was studied across . Hormonal Therapy, Cytotoxics, and Targeted Therapy. The Targeted Therapy is further studied across Monoclonal Antibodies and Small Molecule Inhibitors.

Based on End User, the market was studied across Clinics, Hospitals, and Specialty Centers.

Based on Distribution Channels, the market was studied across Hospital Pharmacies and Retail Pharmacies.

Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. The Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, …

Full story available on Benzinga.com

[ad_2]

Source link